General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Share buy-back

At the annual general meeting of shareholders of Novartis in February 2008, the shareholders of Novartis granted the authorization to the Novartis Board to repurchase Novartis shares up to a maximum amount of CHF 10 billion via a second trading line on the SIX Swiss Exchange.

Official notices in German and French


Novartis registered shares on the second line

ISIN CH0038459415 Ticker NOVNEE

Repurchases of Novartis shares are carried out on a second trading line on the SIX Swiss Exchange, with Novartis as the exclusive buyer.

A shareholder wishing to sell Novartis shares may do so either via the ordinary trading line or via the second line. Novartis shares sold via the second trading line are subject to the Swiss federal withholding tax rate of 35 percent on the difference between the repurchase price of the Novartis share and its nominal value of CHF 0.50. This withholding tax can be reclaimed by qualified investors.

Transaction reporting

Maximum daily repurchase volume

1,614,491 shares
(calculated in accordance with Art. 55b(1)(c) of the Swiss Federal Ordinance on Stock Exchange and Securities Trading)

Stock chart
Q3 Results 2013

On Thursday, April 24, Novartis will announce its results for the first quarter of 2014